

Drug List Per Act 165

IDENTIFIED DRUG LIST PER ACT 165

<u>Brand/ Generic</u>	<u>Brand Name**</u>	<u>Generic Name</u>	<u>Labeler</u>	<u>Therapeutic Class</u>	<u>1 Year Avg. WAC* % Change</u>	<u>5 Year Avg. WAC* % Change</u>
Brand	ABILIFY	Aripiprazole	OTSUKA AMERICA	Quinolinone Derivatives		55.27%
Brand	LANTUS	Insulin Glargine	AVENTIS PHARMACEUTICALS	Human Insulin		89.83%
Brand	HUMIRA	Adalimumab	ABBOTT LABORATORIES	Anti-TNF-alpha - Monoclonal Antibod	27.95%	113.79%
Brand	ENBREL	Etanercept	AMGEN/IMMUNEX	Soluble Tumor Necrosis Factor Recep	16.42%	92.73%
Brand	CRESTOR	Rosuvastatin Calcium	ASTRAZENECA LP	HMG CoA Reductase Inhibitors	20.75%	75.98%
Brand	EPIPEN	Epinephrine	MYLAN SPECIALTY	Anaphylaxis Therapy Agents	32.02%	205.45%
Brand	LATUDA	Lurasidone HCl	SUNOVION PHARMACEUTICALS, INC.	Antipsychotics - Misc.	19.80%	99.68%
Brand	PREVACID	Lansoprazole	TAKEDA PHARMACEUTICALS AMERICA	Proton Pump Inhibitors	20.78%	103.32%
Generic	DOXYCYCLINE HYCLATE	Doxycycline Hyclate	MUTUAL PHARMACEUTICAL COMPANY	Tetracyclines		4787.61%
Generic	PERMETHRIN	Permethrin	PERRIGO PHARMACEUTICALS	Scabicides & Pediculicides	50.00%	

* WAC - Wholesale Acquisition Cost across various strengths, representing different brands/generics and therapeutic classes
 1 Year Average increase > 15%
 5 Year Average increase > 50%